7. The use of claim 6, wherein the delayed or controlled release dosage form provides a C_{max} at least about 50% higher than the C_{max} of the immediate release dosage form.

8. The use of claim 6, wherein the delayed or controlled release dosage form provides a C_{max} up to about 75% higher than the C_{max} of the immediate release dosage form.

9. The use of claim 1, wherein the enteric coating is a composition selected from the group consisting of polymerized gelatin, shellac, methacrylic acid copolymer type C NF, cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose proprionate phthalate, polyvinyl acetate phthalate (PVAP), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate, dioxypropyl methylcellulose succinate, carboxymethyl ethylcellulose (CMEC) , hydroxypropyl methylcellulose acetate succinate (HPMCAS) , and acrylic acid polymers and copolymers, typically formed from methyl acrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate with copolymers of acrylic and methacrylic acid esters.

10. The use of any of the foregoing claims, wherein the medicament results in improvement in liver fibrosis compared to levels before administration of the cysteamine salt or cystamine salt.

11. The use of any of claims 1–9, wherein the medicament results in a reduction in fat content of liver.

12. The use of any of claims 1–9, wherein the medicament results in a reduction in the incidence of or progression of cirrhosis.

13. The use of any of claims 1–9, wherein the medicament results in a reduction in the incidence of hepatocellular carcinoma.

14. The use of any of claims 1–9, wherein the medicament results in a decrease in hepatic aminotransferase levels compared to levels before administration of the cysteamine salt or cystamine salt.

15. The use of any of claims 1–9, wherein the medicament results in a reduction in hepatic transaminase of between 10% to 40% compared to levels before treatment.

16. The use of any of claims 1–9, wherein the medicament results in a reduction in alanine aminotransferase levels in a treated patient to approximately 30%, 20% or 10% above normal ALT levels, or at normal ALT levels (≥ 40 iu/L).

17. The use of any of claims 1–9, wherein the medicament results in a reduction in aspartate aminotransferase levels in a treated patient to approximately 30%, 20% or 10% above normal AST levels or to normal AST levels.